| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of BentrioTM in the prevention and treatment of acute Covid-19 and shall start recruitment in the third quarter 2021 subject to regulatory and ethics committee approval.
"In our studies in human nasal epithelium cells, Bentrio has shown to be highly effective both in protecting against SARS-CoV-2 when applied before infection onset and in reducing infectiousness when applied afterwards", commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. "We now look forward to testing and confirming Bentrio's efficacy also clinically. Despite great progress with vaccination programs, Covid-19 remains a major health risk and concern for many people and many countries worldwide, as evidenced by recent surges in infection rates and the continued emergence of virus variants."
Posted In: EARS
